Patent details

EP3575326 Title: TREATMENT OF CD47+ DISEASE CELLS WITH SIRP ALPHA-FC FUSIONS

The time of generation of the report may vary depending on the number of the selected files and the pages of each file. If the generation of the consolidated PDF file takes long, you may reduce the number of selected files and proceed with the generation of the PDF in batches.
You have not selected any documents

Basic Information

Publication number:
EP3575326
WO Application Number:
Type:
European Patent Granted for NL
Status:
Patent in Force
Publication Title:
Title When Made Available For Viewing:
Reason Lapsed:
Application number:
EP19185175.7
WO Publication Number:
EPO Publication Language:
English
SPC Number:
First Applicant Residence Country:
Canada (CA)
Publications:

Dates

Filing date:
17/12/2013
Grant date:
13/04/2022
EP Publication Date:
04/12/2019
WO Publication Date:
Claims Translations Received Date:
Claims Translation B1 Received Date:
09/06/2022
Claims Translation B2 Received Date:
Claims Translation B3 Received Date:
Lapsed By Non Payment Annual Fee Date:
Renunciation Date:
NullificationDate:
Published:
Due To Cession Date:
Registration date:
13/04/2022
EP B1 Publication Date:
13/04/2022
EP B2 Publication Date:
EP B3 Publication Date:
Description Translation B1 Received Date:
Description Translation B2 Received Date:
Description Translation B3 Received Date:
Expiration date:
16/12/2033
Lapsed By Expiration Date:
Patent Validated Date:
16/06/2022
Revocation Date:
Invalidity Date:
Response To Novelty Search Report Received:
Patent Granting Request:
Lapsed date:

Applicant/holder

From:
03/05/2023
 
 

 

Name:
Pfizer Inc.
Address:
66 Hudson Boulevard East, 10001-2192, New York, N.Y., United States of America (US)

Historical Applicant/holder

From:
03/05/2023
To:
03/05/2023

 

Name:
PF Argentum IP Holdings LLC
Address:
66 Hudson Boulevard East, 10001-2192, New York, N.Y., United States of America (US)

From:
09/06/2022
To:
03/05/2023

 

Name:
PF Argentum IP Holdings LLC
Address:
235 East 42nd Street, 10017, New York, NY., United States of America (US)

From:
13/04/2022
To:
09/06/2022

 

Name:
Trillium Therapeutics Inc.
Address:
2488 Dunwin Drive, Mississauga, Ontario L5L 1J9, Canada (CA)

Agent

Name:
dr. R.C. van Duijvenbode c.s.
From:
15/06/2022
Address:
NLO Postbus 29720, 2502 LS, Den Haag, Netherlands (NL)
To:

Inventor

1

Name:
UGER, Robert Adam
Address:
Richmond Hill, Ontario L4C 7S4, Canada (CA)

2

Name:
SLAVOVA-PETROVA, Penka Slavtcheva
Address:
Toronto, Ontario M8V 3X1, Canada (CA)

3

Name:
PANG, Xinli
Address:
Brampton, Ontario L6R 3H1, Canada (CA)

Priority

Priority Patent Number:
201261738008 P
Priority Date:
17/12/2012
Priority Country:
United States of America (US)

Classification

IPC or IDT classification:
C07K 19/00; A61K 38/16; A61K 38/45; A61P 35/02; C07K 14/705; C07K 16/00; C12N 15/62; A61K 38/00;

Publication

Bulletin

1

Bulletin Heading:
CO
Journal edition number:
20/23
Publication date:
17/05/2023
Description:
Changes in the Netherlands Patent Register

2

Bulletin Heading:
CO
Journal edition number:
25/22
Publication date:
22/06/2022
Description:
Changes in the Netherlands Patent Register

3

Bulletin Heading:
EP3
Journal edition number:
25/22
Publication date:
22/06/2022
Description:
European patents granted for the Netherlands in which a translation was filed ex Article 52 par. 1 of the NL Patent Law 1995

4

Bulletin Heading:
EP2
Journal edition number:
15/22
Publication date:
13/04/2022
Description:
European patents granted for the Netherlands

European Patent Bulletin

1

Issue number:
202221
Publication date:
25/05/2022
Description:
Document reprinted after correction (B8, B9)

2

Issue number:
202216
Publication date:
20/04/2022
Description:
Application number/publication number of the divisional application (Art. 76) changed

3

Issue number:
202215
Publication date:
13/04/2022
Description:
Grant (B1)

Deed

Change of Address

Change Kind/ Decision Type:
Owner
Deed Number:
RC202300936A
Date Registered:
03/05/2023
License Effective Date:
License Expiration Date:
Scope of License:
Deed Filer:
dr. R.C. van Duijvenbode c.s.
Journal Edition Number:
Text:
Deed Status:
Country Code:
Updated License Number:
Terminated License Number:

Changed Pledgee

Name:
Address:

Removed Usufructuary

Name:
Address:

Added Usufructuary

Name:
Address:

Changed Usufructuary

Name:
Address:

Change of owner(s)

Change Kind/ Decision Type:
Assignment
Deed Number:
RC202300936B
Date Registered:
03/05/2023
License Effective Date:
License Expiration Date:
Scope of License:
Deed Filer:
dr. R.C. van Duijvenbode c.s.
Journal Edition Number:
Text:
Deed Status:
Country Code:
Updated License Number:
Terminated License Number:

Added Owner(s)

Name:
Pfizer Inc.
Address:
66 Hudson Boulevard East, 10001-2192, New York, N.Y., United States of America (US)

Changed Pledgee

Name:
Address:

Removed Usufructuary

Name:
Address:

Added Usufructuary

Name:
Address:

Changed Usufructuary

Name:
Address:

Change of owner(s)

Change Kind/ Decision Type:
Assignment
Deed Number:
RC202201472A
Date Registered:
09/06/2022
License Effective Date:
License Expiration Date:
Scope of License:
Deed Filer:
dr. R.C. van Duijvenbode c.s.
Journal Edition Number:
Text:
Deed Status:
Country Code:
Updated License Number:
Terminated License Number:

Added Owner(s)

Name:
PF Argentum IP Holdings LLC
Address:
235 East 42nd Street, 10017, New York, NY., United States of America (US)

Changed Pledgee

Name:
Address:

Removed Usufructuary

Name:
Address:

Added Usufructuary

Name:
Address:

Changed Usufructuary

Name:
Address:

Annual Fee

Annual Fee(s) Due Date:
31/12/2025
Annual Fee Number:
13
Annual Fee Amount:
700 Euro
Last Annual Payment Date:
14/11/2024
Last Annual Fee Paid Number:
12
Last Annual Fee Paid Amount:
600 Euro
Payer:
Master Data Center
Filing date Document type Document Description Number of pages File Type
15/06/2022 Outgoing Correspondence Letter no formal defects 1 PDF /8/4/1/4/8/0800784148/docs/ep19185175.7_0_487294l271.pdf
09/06/2022 Claims First filed claims 2 PDF /8/4/1/4/8/0800784148/docs/ep19185175.7_1_claims20220609074517013.pdf